---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039743"
form_type: "8-K"
ticker: "CNTN"
cik: "0001861657"
company_name: "Canton Strategic Holdings, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:32:51.221884+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tharimmune licenses clinical-stage TH104 for chronic pruritis; PBC Phase 2 trial planned

## Summary
- Exclusive worldwide license from Avior for TH104 (AV104) and TH103; targets chronic pruritis in PBC, an orphan liver disease.
- Upfront mid-six-digit fee plus installments; up to $24.25M in development milestones plus sales-based payments and royalties.
- Plans to initiate Phase 2 trial in PBC patients within ~12 months after FDA alignment; expects top-line data thereafter.
- TH104 uses buccal film delivery with dual mechanism on μ-opioid and κ-opioid receptors and IL-17 inhibition.
- CEO Randy Milby says license agreement represents shift to clinical development focus.

## SEC filing metadata
- accession: 0001493152-23-039743
- form_type: 8-K
- ticker: CNTN
- cik: 0001861657
- company_name: Canton Strategic Holdings, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861657/000149315223039743/0001493152-23-039743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861657/000149315223039743/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039743
- JSON: https://secwatch.observer/filing/0001493152-23-039743.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039743.txt

## Key facts
- Material Agreements
  Canton Strategic Holdings, Inc. entered into Avior Patent License Agreement with Avior Inc. d/b/a Avior Bio, LLC valued at $24,250,000 (effective 2023-11-03).
  - Action: entry
  - Agreement: license
  - Counterparty: Avior Inc. d/b/a Avior Bio, LLC
  - Value: $24,250,000
  - Effective: 2023-11-03
  source text: Tharimmune, Inc. (the “Company”) entered into a patent license agreement (the “Avior Patent License Agreement”) with Avior Inc. d/b/a Avior Bio, LLC (“Avior”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861657/000149315223039743/0001493152-23-039743-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.